Changes in oestrogen receptor-α and -β during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells
Authors:
- P.D. DarbrePDP.D. Darbre
- 1 April 2006
- journal article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 99 (1) , 19-32
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Mechanisms of tamoxifen resistanceEndocrine-Related Cancer, 2004
- Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathwaysThe Journal of Steroid Biochemistry and Molecular Biology, 2003
- Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 CellsEndocrinology, 2003
- Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivationThe Journal of Steroid Biochemistry and Molecular Biology, 2002
- Tamoxifen (‘Nolvadex’): a reviewCancer Treatment Reviews, 2002
- Fulvestrant (Faslodex™): current status in the therapy of breast cancerExpert Review of Anticancer Therapy, 2002
- Insulin-like Growth Factor Receptor Levels Are Regulated by Cell Density and by Long Term Estrogen Deprivation in MCF7 Human Breast Cancer CellsJournal of Biological Chemistry, 2001
- Loss of growth inhibitory effects of retinoic acid in human breast cancer cells following long-term exposure to retinoic acidBritish Journal of Cancer, 2000
- Short- and long-term estrogen deprivation of T47D human breast cancer cells in cultureEuropean Journal of Cancer and Clinical Oncology, 1989
- Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) cultureEuropean Journal of Cancer and Clinical Oncology, 1987